glp 1 nature medicine This is a review of the drug class and what's coming down the pike; it's not about perioperative issues. Article PDF: https://bit.ly/New-GLP1s Expanding applications of therapies based

No shakes

MNTIs arising in other sites including the ear 5 , pineal 6 , epididymis 2, 7 , femur 2 and other locations have also been described

According to the UK SmPC, the most common side effects include: Nausea (very common, affecting more than 1 in 10 people): Usually most pronounced during the first few weeks of treatment and often diminishes with continued use Diarrhoea (common, affecting up to 1 in 10 people): Typically mild to moderate in severity Vomiting (common): More frequent at higher doses Constipation (common): May occur alongside other gastrointestinal effects Abdominal pain or discomfort (common): Relatively frequent during treatment initiation Decreased appetite (very common): An expected effect related to the medication's action Dyspepsia/indigestion (common): May contribute to discomfort after eating Beyond gastrointestinal effects, other recognised adverse reactions include injection site reactions (redness, itching, or swelling at the subcutaneous injection site), fatigue , and dizziness

Routine follow-up detects early negative changes in glucose control